Core Insights - The upcoming Milan Cortina 2026 Winter Olympics and Paralympics signify a shift in how sports are experienced and interpreted culturally, rather than just in the competition itself [2] Consumer Insights - Consumers are increasingly viewing major sporting events as cultural moments, where identity and personal values play a significant role alongside athletic performance [3] - Nearly 60% of consumers globally believe athletes should express their full identity beyond sports, indicating a demand for brands to communicate with cultural awareness and relevance [4] Brand Strategy - Younger generations are particularly interested in multidimensional narratives of athletes, which include their roles as creators, entrepreneurs, and advocates, suggesting that off-field stories are as influential as on-field actions [5] - For small and medium-sized businesses (SMBs), the focus should be on emotional storytelling that resonates with audiences, rather than competing with elite athletes or official sponsors [6] Marketing Recommendations - Brands should lead with action while also showcasing the human side of athletes, providing context that highlights personality and community [10] - Authentic representation across various demographics is crucial, especially during the Paralympics, where visuals should feel natural and relatable [11] - Emphasizing cultural relevance over Olympic clichés is essential; brands should focus on the emotions evoked by the Games, such as resilience and belonging, rather than just the event itself [12]

Core Insights - SOLOWIN HOLDINGS has received an In-Principle Approval letter for a stablecoin license from the Central Bank of Bahrain for its subsidiary AX Coin, pending final regulatory approval [1][2] Company Overview - SOLOWIN HOLDINGS (NASDAQ: AXG) is a leading financial technology firm established in 2016, focusing on bridging traditional and decentralized finance through secure and compliant financial infrastructure [2] - The company operates through its subsidiaries, including AlloyX Group and AX Coin, and offers integrated digital asset solutions for global investors and institutions [2] - The firm is backed by prominent international institutional investors and aims to manage compliant and transparent digital assets closely linked to the real economy [2] Strategic Goals - The company aims to launch a compliant stablecoin within the regulatory framework and expand AlloyX Group's stablecoin ecosystem across the Middle East and Africa (MEA) region and beyond [2]

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial results for the full year and fourth quarter 2025 on Friday, February 6, 2026, before the market opens. Conference Call and Webcast Management will host a conference call and webcast to review Perella Weinberg’s results on the same day at 9:00AM ET. A webcast of the conference call will be available to the public on a listen-on ...

Core Insights - GRI Bio, Inc. announced positive data from its Phase 2a clinical study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF), indicating potential disease-modifying effects and therapeutic differentiation [1][10] Gene Expression and Mechanism - RNA-sequencing data showed significant improvement in genes related to lung injury, myofibroblast activation, and fibrosis progression in GRI-0621 treated subjects compared to placebo, validating previous biomarker findings [2][4] - The treatment demonstrated modulation of differentially expressed genes (DEGs) linked to key disease drivers, supporting a mechanism of fibrosis resolution and tissue repair rather than mere symptomatic management [3][4] Lung Regeneration Evidence - GRI-0621 treatment was associated with repair of the alveolar basement membrane and transition of AT2 to AT1 epithelial cells, indicating true lung regeneration rather than just slowing disease progression [5][6] - Earlier data indicated changes in type IV collagen serum biomarkers, suggesting an alveolar repair mechanism, which is now supported by new gene expression findings [6] Consistency Across Data - The new results reinforce previously announced topline data, showing that GRI-0621 treatment led to decreased neutrophil activity, reduced synthesis of fibrillar collagens, and lower levels of pro-fibrotic cytokines [8][9] - The treatment was well-tolerated, differentiating it from existing options that primarily slow disease decline while having significant side effects [7][10] Clinical Study Outcomes - The Phase 2a study met its primary endpoint with favorable safety and tolerability, and multiple secondary endpoints indicative of disease-modifying activity were achieved [12] - Improvements were noted in forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline in FVC at 12 weeks compared to standard care [12]

Core Insights - The study led by the National Cancer Institute (NCI) demonstrated a median progression-free survival (PFS) of 9.6 months for the investigational drug PDS01ADC in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][2] - The combination therapy showed a median PSA decline of 40%, with 6 out of 16 patients achieving more than a 50% decline [2] - PDS Biotech aims to advance PDS01ADC as a key component of its immuno-oncology pipeline, reinforcing its potential to enhance existing therapies across various solid tumor types [3] Company Overview - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming immune responses to cancer [4] - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [4] - PDS Biotech's lead investigational therapy, PDS0101 (Versamune HPV), is being developed in combination with standard immune checkpoint inhibitors and PDS01ADC [4]

Core Insights - Itron is enhancing its collaboration with Microsoft to leverage AI for improving utility operations, focusing on efficiency, resilience, and customer engagement [1][3] - The introduction of the Itron Intelligent Edge Operating System (IEOS) Connector for Microsoft 365 Copilot allows utilities to utilize natural-language queries to access insights from Itron's data management systems [2][3] - The partnership aims to redefine grid edge intelligence by applying AI to optimize operations and enhance customer experiences, addressing the challenges utilities face in modernizing infrastructure and reducing costs [3] Company Developments - Itron is launching the IEOS Connector, which integrates with Microsoft 365 Copilot, enabling utilities to access data on consumption patterns, outage history, and other operational insights [2] - The collaboration will automate exception handling in utility processes, such as billing, improving accuracy and accelerating revenue cycles [3] - Itron and Microsoft will showcase their innovations and AI roadmap at DTECH from February 2-5, 2026, highlighting their commitment to AI-driven grid modernization [4] Industry Impact - The partnership is positioned to help utilities achieve measurable gains in efficiency and resilience while preparing for a more sustainable grid [3][6] - Itron's solutions will be made available through the Microsoft Marketplace, facilitating easier access for utilities and partners [6] - The collaboration supports immediate operational improvements and lays the groundwork for a future powered by AI in utility management [6]

Core Insights - The FDA has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis based on positive interim clinical results from the NEXICART-2 Phase 2 trial [1][3][4] Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis, focusing on developing innovative therapies for this condition [9] - The company’s lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation and teach the immune system to eliminate toxic light chains [8][9] Clinical Development - NEXICART-2 is an ongoing multi-site U.S. Phase 2 clinical trial aimed at enrolling 40 patients to evaluate the efficacy of NXC-201 in relapsed/refractory AL Amyloidosis [5] - Final data from the NEXICART-2 trial is expected to be released this year, followed by a planned Biologics License Application (BLA) submission [1][4] Market Context - The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% per year, reaching approximately 38,500 patients by 2026 [6] - The AL Amyloidosis market was valued at $3.6 billion in 2017 and is anticipated to reach $6 billion by 2025 [7]

Core Insights - EdgeMode has expanded its joint venture with BAIF, adding approximately 2GW of new planned capacity, bringing the total to 3.5GW across Europe and Central America [1][2][3] Group 1: Expansion Details - The newly added projects include DC Villasequilla (600MW), DC Tomelloso (450MW), and DC Tocumen (1,000MW), with a total of 2.5GW in Spain and 1GW in Panama [2] - The expansion enhances EdgeMode's position as a leading AI data center infrastructure developer, focusing on power-secured and Ready-to-Build (RTB) projects [3][4] Group 2: Strategic Advantages - The agreement brings additional local development resources and market expertise, improving execution capabilities in Spain and Panama [4] - EdgeMode's strategy includes securing land, power, and permitting early, which allows for faster deployment of compute capacity [8] Group 3: Market Demand and Trends - There is a growing demand for AI data center capacity, with industry analysts estimating a double-digit annual growth rate for global AI data center capacity over the next decade [7] - The expansion reflects increasing demand from hyperscale and enterprise off-takers for large-scale, power-secured AI infrastructure [5][6]

Core Insights - Lakeland Industries, Inc. has received an order from the Belgian Federal Police and Local Police departments for certified safety footwear, marking the third award in a six-year tender agreement [1][3]. Group 1: Company Overview - Lakeland Fire + Safety is a leading global manufacturer of protective clothing and apparel for various sectors including industry, healthcare, and first responders [1][5]. - The company offers a comprehensive line of fire services and industrial protective clothing, along with decontamination, repair, and rental services [5]. Group 2: Market Presence and Performance - The Belgian Federal Police consists of approximately 12,300 officers and civilian personnel, while there are around 30,000 local police officers across 196 local police areas in Belgium [2]. - The order signifies the strong performance, comfort, and durability of Lakeland's footwear, which has been validated during end-user testing [3]. - The footwear's quality and proven supply reliability have been key strengths in maintaining a long-term partnership with the Belgian police forces [3]. Group 3: Future Opportunities - There is potential for further orders in future contract cycles, indicating a positive outlook for continued collaboration with Belgium's police forces [3]. - The transaction highlights the global reach of Lakeland's products across various geographies and industry verticals, with established relationships and local market knowledge being advantageous [4]. - The company aims to strengthen its leading global fire brand and explore attractive cross-selling opportunities across its markets [4].

American Rebel Holdings Inc American Rebel Light North and North Central Florida Tri-Eagle Sales to Drive American Rebel Light Beer Availability in Key Markets, Including Management of Gainesville Raceway as the Official Beer, Supporting Chain Expansions and High-Profile On-Premise Opportunities in Florida and the Southeast in 2026 Nashville, TN, Jan. 28, 2026 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), America’s Patriotic Brand, and maker of Ame ...